Profound MedicalPROF -1.77%73 Net Current Asset Value is $1.53 as of Mar. 2026, which is 67% below its 10-year median of 4.61. GuruFocus rates PROF with a GF Score™ of 73/100 and a GF Value™ of $14.28 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 568 Medical Devices & Instruments companies, Profound Medical ranks better than 50.7% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Profound Medical's net current asset value per share for the quarter that ended in Mar. 2026 was $1.53.
The historical rank and industry rank for Profound Medical's Net Current Asset Value or its related term are showing as below:
PROF'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.63 Med: 4.61 Max: 31.95
Current: 4.9
During the past 12 years, the highest Price-to-Net-Current-Asset-Value Ratio of Profound Medical was 31.95. The lowest was 1.63. And the median was 4.61.
PROF's Price-to-Net-Current-Asset-Value is ranked better than 50.7% of 568
companies
in the Medical Devices & Instruments industry
Industry Median: 5.11
vs PROF: 4.90
Profound Medical (NAS:PROF) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Profound Medical Net Current Asset Value Related Terms
Profound Medical Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Profound Medical's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PROF vs ABT, SYK, MDT: Net Current Asset Value Comparison
For the Medical Devices subindustry, Profound Medical's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Profound Medical Price-to-Net-Current-Asset-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Profound Medical's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Profound Medical's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $1.53 mean?
Profound Medical (PROF) has a Net Current Asset Value of $1.53 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Profound Medical and its competitors. This is 67% below median its historical median of 4.61. Over the past decade, Profound Medical's Net Current Asset Value has ranged from 1.63 to 31.95. According to the industry distribution chart, Profound Medical ranks #280 out of 568 companies in the Medical Devices & Instruments industry, placing it in the top 49.3%.
Is Profound Medical's Net Current Asset Value too high?
Profound Medical's current Net Current Asset Value of $1.53 is 67% below median its 10-year median of 4.61. Over the past 10 years, this metric has ranged from a low of 1.63 to a high of 31.95. The Medical Devices & Instruments industry median Net Current Asset Value is 5.11. Profound Medical's value of $1.53 is 70.1% below this industry median. Based on the distribution chart, Profound Medical ranks #280 out of 568 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Profound Medical has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Profound Medical's Net Current Asset Value compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Profound Medical ranks #280 out of 568 companies for Net Current Asset Value. This puts Profound Medical in the upper half of its industry. The industry median Net Current Asset Value is 5.11. Profound Medical's value of $1.53 is 70.1% below this benchmark. Historically, Profound Medical's own Net Current Asset Value has ranged from 1.63 to 31.95 over the past decade. While the company's 10-year median is 4.61 vs. the industry median of 5.11, Profound Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Devices & Instruments company?
The median Net Current Asset Value among Medical Devices & Instruments companies is 5.11, based on 568 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Profound Medical's current Net Current Asset Value of $1.53 is 70.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Profound Medical and its competitors. For the Medical Devices & Instruments industry, the median Net Current Asset Value is 5.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Profound Medical's current Net Current Asset Value is $1.53, which is 67% below median its own 10-year median of 4.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Profound Medical stock overvalued right now?
Based on GuruFocus' analysis, Profound Medical (PROF) is currently considered Possible Value Trap. The stock's GF Value™ is $14.28, compared to a current price of $7.21 — trading 49.5% below its estimated fair value. The current Net Current Asset Value is $1.53, which is 67% below median its 10-year median of 4.61 and 70.1% below the Medical Devices & Instruments industry median of 5.11. Profound Medical's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Profound Medical (PROF), the current Net Current Asset Value is $1.53 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Profound Medical (PROF) Overvalued in 2026?
Based on GuruFocus' analysis, Profound Medical stock appears to be undervalued.
The current stock price of $7.21 is trading 49.5% below its estimated GF Value™ of $14.28.
GuruFocus considers Profound Medical to be Possible Value Trap.
Key valuation signals for PROF:
Net Current Asset Value: $1.53 (67% below median its 10-year median of 4.61)
GF Value™: $14.28 vs. price of $7.21 (49.5% below fair value)
Industry Position: 70.1% below the Medical Devices & Instruments median (#280 of 568)
No single metric tells the full story. See the PROF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
73GF Score
Get the complete analysis for PROF
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PROF has been successfully added to your 
